A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients

Trial Profile

A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Tofacitinib (Primary) ; Ciclosporin; Corticosteroids; Mycophenolate mofetil; Mycophenolate sodium
  • Indications Renal transplant rejection
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ND
  • Sponsors Pfizer
  • Most Recent Events

    • 31 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 May 2015 Planned End Date changed from 1 May 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.
    • 28 Mar 2015 Planned number of patients changed from 180 to 300 as reported by European Clinical Trial Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top